List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6761217/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Physical Frailty Phenotype and the Development of Geriatric Syndromes in Older Adults with Coronary Heart Disease. American Journal of Medicine, 2021, 134, 662-671.e1.	0.6	19
2	Frailty and cardiovascular outcomes in the National Health and Aging Trends Study. European Heart Journal, 2021, 42, 3856-3865.	1.0	73
3	Transcatheter Aortic Valve Replacement in Low-Population Density Areas. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006245.	0.9	17
4	TCT-749 The Influence of Severe Aortic Valve Stenosis on 5-Year Economic Outcomes Among Older Medicare Beneficiaries. Journal of the American College of Cardiology, 2019, 74, B735.	1.2	0
5	Reply. Journal of the American College of Cardiology, 2019, 74, 824-825.	1.2	0
6	Frailty Among Older Adults With Acute Myocardial Infarction and Outcomes From Percutaneous Coronary Interventions. Journal of the American Heart Association, 2019, 8, e013686.	1.6	55
7	Percutaneous Coronary Intervention in Older Patients With ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock. Journal of the American College of Cardiology, 2019, 73, 1890-1900.	1.2	45
8	Temporal Trends of Percutaneous Coronary Interventions in Older Adults With Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2019, 12, e007812.	1.4	13
9	Influence of operator experience and PCI volume on transfemoral access techniques: A collaboration of international cardiovascular societies. Cardiovascular Revascularization Medicine, 2018, 19, 143-150.	0.3	2
10	Health Care Costs After Cardiac Arrest in the United States. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005689.	2.1	31
11	Alternative access for transcatheter aortic valve replacement in older adults: A collaborative study from France and United States. Catheterization and Cardiovascular Interventions, 2018, 92, 1182-1193.	0.7	26
12	PERCUTANEOUS CORONARY INTERVENTION IN ADULTS AGE 75 YEARS OR OLDER WITH ST ELEVATION MYOCARDIAL INFARCTION AND CARDIOGENIC SHOCK. Journal of the American College of Cardiology, 2017, 69, 1103.	1.2	18
13	PREVENTION OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED PATIENTS: FROM INADEQUATE TO OVER-PROPHYLAXIS. Journal of the American College of Cardiology, 2017, 69, 1861.	1.2	25
14	VENOUS THROMBOEMBOLISM PROPHYLAXIS: NEED OF CONTINUOUS ASSESSMENT DUE TO CHANGES IN RISK DURING THE SAME HOSPITALIZATION. Journal of the American College of Cardiology, 2017, 69, 1862.	1.2	0
15	Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from BARI-2D trial. International Journal of Cardiology, 2017, 241, 35-40.	0.8	14
16	Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry®–Get With The Guidelines (GWTG)®. American Heart Journal, 2017, 194, 16-24.	1.2	28
17	Transfemoral Approach for CoronaryÂAngiography and Intervention. JACC: Cardiovascular Interventions, 2017, 10, 2269-2279.	1.1	32
18	Venous Thromboembolism Prophylaxis: Inadequate and Overprophylaxis When Comparing Perceived Versus Calculated Risk. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 242-247.	1.2	5

MAURO MOSCUCCI

#	Article	IF	CITATIONS
19	Improvements in Outcomes and Disparities of ST-Segment–Elevation Myocardial Infarction Care. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	7
20	Why Aren't Our Digital Solutions Working for Everyone?. AMA Journal of Ethics, 2017, 19, 1116-1124.	0.4	21
21	Predicting In-Hospital Mortality in PatientsÂWith Acute Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 626-635.	1.2	166
22	The association between in-hospital hemoglobin changes, cardiovascular events, and mortality in acute decompensated heart failure: Results from the ESCAPE trial. International Journal of Cardiology, 2016, 222, 531-537.	0.8	14
23	Influence of Total Coronary Occlusion on Clinical Outcomes (from the Bypass Angioplasty) Tj ETQq1 1 0.7843	14 rgBT /Ov	erlock 10 Tf 5
24	Predicting emergency coronary artery bypass graft following PCI: application of a computational model to refer patients to hospitals with and without onsite surgical backup. Open Heart, 2015, 2, e000243.	0.9	2
25	Association between anti-human heat shock protein-60 and interleukin-2 with coronary artery calcium score. Heart, 2015, 101, 436-441.	1.2	14
26	New-onset versus prior history of atrial fibrillation: Outcomes from the AFFIRM trial. American Heart Journal, 2015, 170, 156-163.e1.	1.2	11
27	State Mandated Public Reporting and Outcomes of Percutaneous Coronary Intervention in the United States. American Journal of Cardiology, 2015, 115, 1494-1501.	0.7	27
28	Public Reporting of Percutaneous Coronary Intervention Outcomes. Journal of the American College of Cardiology, 2015, 65, 1127-1129.	1.2	6
29	Abstract 15481: LV Systolic Dysfunction is Improved by TAVR: Insights From the French-American Registry. Circulation, 2015, 132, .	1.6	0
30	Impact of CMS coverage decision on access to transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2014, 84, 114-121.	0.7	5
31	Safety of transradial cardiac catheterization in patients with endâ€stage liver disease. Catheterization and Cardiovascular Interventions, 2014, 83, 360-366.	0.7	31
32	Transient variations of transthoracic impedance as a predictor of heart failure and death in patients with implanted defibrillators. International Journal of Cardiology, 2014, 175, 473-477.	0.8	2
33	Preprocedural statin use in patients undergoing percutaneous coronary intervention. American Heart Journal, 2014, 168, 110-116.e3.	1.2	5
34	The incidence of acute kidney injury after cardiac catheterization or PCI: A comparison of radial vs. femoral approach. International Journal of Cardiology, 2014, 173, 595-597.	0.8	26
35	QRS Duration on Electrocardiography and Cardiovascular Mortality (from the National Health and) Tj ETQq1 1	0.784314 rg 0.7	gBT /Overlock
36	Current medical management of stable coronary artery disease before and after elective percutaneous coronary intervention. American Heart Journal, 2013, 165, 778-784.	1.2	8

#	Article	IF	CITATIONS
37	The association between patient race, treatment, and outcomes of patients undergoing contemporary percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). American Heart Journal, 2013, 165, 893-901.e2.	1.2	26
38	Differences in the outcome of patients undergoing percutaneous coronary interventions at teaching versus non-teaching hospitals. American Heart Journal, 2013, 166, 401-408.	1.2	12
39	Electrocardiographic Abnormalities and Reclassification of Cardiovascular Risk: Insights from NHANES-III. American Journal of Medicine, 2013, 126, 319-326.e2.	0.6	11
40	Correlation of CHADS2 and CHA2DS2-VASc Scores with Transesophageal Echocardiography Risk Factors for Thromboembolism in a Multiethnic United States Population with Nonvalvular Atrial Fibrillation. Journal of the American Society of Echocardiography, 2013, 26, 175-184.	1.2	38
41	ST-T Wave Abnormality in Lead aVR and Reclassification of Cardiovascular Risk (from the National) Tj ETQq1 1	0.784314 r 0.7	gBT_/Overloc
42	Outcome of Percutaneous Coronary Intervention Following Recent Surgery. American Journal of Cardiology, 2013, 112, 1580-1585.	0.7	3
43	Contemporary Use of Prasugrel in Clinical Practice. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 293-298.	0.9	33
44	Comparative Safety of Vascular Closure Devices and Manual Closure Among Patients Having Percutaneous Coronary Intervention. Annals of Internal Medicine, 2013, 159, 660.	2.0	29
45	Contrast-Induced Acute Kidney Injury. Circulation: Cardiovascular Interventions, 2012, 5, 741-743.	1.4	2
46	Progress for Stroke Prevention With Atrial Fibrillation. Circulation, 2012, 125, 1577-1583.	1.6	18
47	Progress for Stroke Prevention With Atrial Fibrillation. Stroke, 2012, 43, 1179-1185.	1.0	8
48	Public Reporting of PCI Outcomes and Quality of Care. JAMA - Journal of the American Medical Association, 2012, 308, 1478.	3.8	8
49	The changing definition of contrast-induced nephropathy and its clinical implications: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). American Heart Journal, 2012, 163, 829-834.	1.2	78
50	Isolated Nonspecific ST-Segment and T-Wave Abnormalities in a Cross-Sectional United States Population and Mortality (from NHANES III). American Journal of Cardiology, 2012, 110, 521-525.	0.7	24
51	Contemporary Use and Effectiveness of N-Acetylcysteine in Preventing Contrast-Induced Nephropathy Among Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 98-104.	1.1	38
52	Renal Function-Based Contrast Dosing to Define Safe Limits of Radiographic Contrast Media in Patients Undergoing Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2011, 58, 907-914.	1.2	271
53	The association of sex with outcomes among patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction in the contemporary era: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). American Heart Journal, 2011, 161, 106-112.e1.	1.2	97
54	Trends and disparities in referral to cardiac rehabilitation after percutaneous coronary intervention. American Heart Journal, 2011, 161, 544-551.e2.	1.2	67

#	Article	IF	CITATIONS
55	Duration of evidence-based medical therapy and the hazard for atherothrombotic events following percutaneous coronary intervention. International Journal of Cardiology, 2011, 153, 262-266.	0.8	3
56	Effect of Performing Real Time Three-Dimensional Transesophageal Echocardiography in Addition to Two-Dimensional Transesophageal Echocardiography on Operator Diagnostic Confidence. Echocardiography, 2011, 28, 235-242.	0.3	3
57	Outcome of Contemporary Percutaneous Coronary Intervention in the Elderly and the Very Elderly: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Clinical Cardiology, 2011, 34, 549-554.	0.7	28
58	How A Regional Collaborative Of Hospitals And Physicians In Michigan Cut Costs And Improved The Quality Of Care. Health Affairs, 2011, 30, 636-645.	2.5	258
59	Medical Reversal, Clinical Trials, and the "Late―Open Artery Hypothesis in Acute Myocardial Infarction. Archives of Internal Medicine, 2011, 171, 1643.	4.3	2
60	Temporal Trends in the Use of Drugâ€eluting Stents for Approved and Offâ€label Indications: A Longitudinal Analysis of a Large Multicenter Percutaneous Coronary Intervention Registry. Clinical Cardiology, 2010, 33, 111-116.	0.7	19
61	Retroperitoneal Hematoma After Percutaneous Coronary Intervention: Prevalence, Risk Factors, Management, Outcomes, and Predictors of Mortality. JACC: Cardiovascular Interventions, 2010, 3, 845-850.	1.1	76
62	Safety and efficacy of thrombectomy in patients undergoing primary percutaneous coronary intervention for Acute ST elevation MI: A Meta-Analysis of Randomized Controlled Trials. BMC Cardiovascular Disorders, 2010, 10, 10.	0.7	67
63	Racial and Ethnic Differences in the Treatment of Acute Myocardial Infarction. Circulation, 2010, 121, 2294-2301.	1.6	137
64	Defining the Optimal Degree of Heparin Anticoagulation for Peripheral Vascular Interventions. Circulation: Cardiovascular Interventions, 2010, 3, 593-601.	1.4	36
65	Trends in Door-to-Balloon Time and Mortality in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Archives of Internal Medicine, 2010, 170, 1842-9.	4.3	130
66	Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: An analysis from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) percutaneous coronary intervention registry. American Heart Journal, 2010, 159, 677-683.e1.	1.2	98
67	The relative renal safety of iodixanol and low-osmolar contrast media in patients undergoing percutaneous coronary intervention. Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Journal of Invasive Cardiology, 2010, 22, 467-72.	0.4	12
68	Patient Comprehension of an Interactive, Computer-Based Information Program for Cardiac Catheterization. Archives of Internal Medicine, 2009, 169, 1907.	4.3	64
69	Percutaneous closure of an iatrogenic atrial septal defect. Catheterization and Cardiovascular Interventions, 2009, 73, 267-271.	0.7	12
70	The Relative Renal Safety of Iodixanol Compared With Low-Osmolar Contrast Media. JACC: Cardiovascular Interventions, 2009, 2, 645-654.	1.1	181
71	Anemia and blood transfusion: Prognostic implications in patients undergoing contemporary percutaneous coronary intervention. Current Cardiology Reports, 2009, 11, 363-368.	1.3	4
72	Percutaneous Coronary Intervention Complications and Guide Catheter Size. JACC: Cardiovascular Interventions, 2009, 2, 636-644.	1.1	46

#	ACULATION AND A CONTRACT A	IF	CITATIONS
73	procedures a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians task Force on Clinical Competence and Training (writing) Tj ETQq1	1 0.784314 0.7	f rgBT /Over
74	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. American Heart Journal, 2009, 158, 881-886.e1.	1.2	32
75	Radiation Dose From Cardiac Computed Tomography Before and After Implementation of Radiation Dose–Reduction Techniques. JAMA - Journal of the American Medical Association, 2009, 301, 2340.	3.8	210
76	The Relative Safety and Efficacy of Abciximab and Eptifibatide in Patients Undergoing Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2008, 51, 529-535.	1.2	94
77	Current role of sodium bicarbonate–based preprocedural hydration for the prevention of contrast-induced acute kidney injury: A meta-analysis. American Heart Journal, 2008, 156, 414-421.	1.2	107
78	Screening for Myocardial Infarction and Ischemic Stroke. Neuroepidemiology, 2007, 29, 96-100.	1.1	1
79	Behavioral Factors, Bias, and Practice Guidelines in the Decision to Use Percutaneous Coronary Interventions for Stable Coronary Artery Disease. Archives of Internal Medicine, 2007, 167, 1573.	4.3	5
80	ACCF/AHA/SCAI 2007 Update of the Clinical Competence Statement on Cardiac Interventional Procedures. Circulation, 2007, 116, 98-124.	1.6	209
81	Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?. Circulation, 2007, 116, 2793-2801.	1.6	213
82	Summary of Evidence Regarding Hospital Strategies to Reduce Door-to-Balloon Times for Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Critical Pathways in Cardiology, 2007, 6, 91-97.	0.2	56
83	ACCF/AHA/SCAI 2007 Update of the Clinical Competence Statement on Cardiac Interventional Procedures. Journal of the American College of Cardiology, 2007, 50, 82-108.	1.2	73
84	Temporal Trends, Safety, and Efficacy of Bivalirudin in Elective Percutaneous Coronary Intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Journal of Interventional Cardiology, 2007, 20, 197-203.	0.5	10
85	Meta-Analysis of Randomized Trials of Drug-Eluting Stents Versus Bare Metal Stents in Patients With Diabetes Mellitus. American Journal of Cardiology, 2007, 99, 1399-1402.	0.7	56
86	Temporal Trends in Antiplatelet/Antithrombotic Use in Acute Coronary Syndromes and In-Hospital Major Bleeding Complications. American Journal of Cardiology, 2007, 100, 1359-1363.	0.7	13
87	Improving Outcomes of Percutaneous Coronary Intervention through the Application of Guidelines and Benchmarking: Reduction of Major Bleeding and Blood Transfusion as a Model. Clinical Cardiology, 2007, 30, II44-II48.	0.7	2
88	Blood Transfusion and In-hospital Outcomes in Anemic Patients with Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Clinical Cardiology, 2007, 30, II49-II56.	0.7	43
89	Reducing the Door-to-Balloon Time for Myocardial Infarction with ST-Segment Elevation. New England Journal of Medicine, 2006, 355, 2364-2365.	13.9	18
90	Door-to-Balloon Time in Primary Percutaneous Coronary Intervention. Circulation, 2006, 113, 1048-1050.	1.6	33

MAURO MOSCUCCI

#	Article	IF	CITATIONS
91	Association of a Continuous Quality Improvement Initiative With Practice and Outcome Variations of Contemporary Percutaneous Coronary Interventions. Circulation, 2006, 113, 814-822.	1.6	152
92	Partnering with payers to improve surgical quality: The Michigan plan. Surgery, 2005, 138, 815-820.	1.0	108
93	Development of a multicenter peripheral arterial interventional database: The PVD-QI2. American Heart Journal, 2005, 149, 1003-1008.	1.2	34
94	Incidence, risk factors, and prognosis of inhospital heart failure after percutaneous coronary intervention: Insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). American Heart Journal, 2005, 150, 455-458.	1.2	13
95	Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. American Journal of Medicine, 2005, 118, 843-849.	0.6	191
96	Public Reporting and Case Selection for Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2005, 45, 1759-1765.	1.2	164
97	Relationship Between Operator Volume and Adverse Outcome in Contemporary Percutaneous Coronary Intervention Practice. Journal of the American College of Cardiology, 2005, 46, 625-632.	1.2	102
98	Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes. Circulation, 2004, 109, 745-749.	1.6	287
99	Prognostic Implication of Anemia on In-Hospital Outcomes After Percutaneous Coronary Intervention. Circulation, 2004, 110, 271-277.	1.6	147
100	Coronary Revascularization before Noncardiac Surgery. New England Journal of Medicine, 2004, 351, 2861-2863.	13.9	20
101	Double-wire technique for access into a protruding aorto-ostial stent for treatment of in-stent restenosis. Catheterization and Cardiovascular Interventions, 2004, 62, 214-217.	0.7	28
102	ls acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. American Journal of Medicine, 2004, 117, 938-947.	0.6	191
103	Prognostic implication of troponin I elevation after percutaneous coronary intervention. American Journal of Cardiology, 2003, 91, 1272-1274.	0.7	67
104	Long-term prognostic implication of extracardiac vascular disease in patients undergoing percutaneous coronary intervention. American Journal of Cardiology, 2003, 92, 964-966.	0.7	19
105	Frequency and prognosis of emergency coronary artery bypass grafting after percutaneous coronary intervention for acute myocardial infarction. American Journal of Cardiology, 2003, 92, 967-969.	0.7	8
106	Impact of extracardiac vascular disease on acute prognosis in patients who undergo percutaneous coronary interventions (data from the Blue Cross & Blue Shield of Michigan Cardiovascular) Tj ETQq0 0 0 rgBT /O	ve olo rck 10) Tfz50 137 To
107	Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). European Heart Journal, 2003, 24, 1815-1823.	1.0	800

From guidelines to clinical practice: the impact of hospital and geographical characteristics on108temporal trends in the management of acute coronary syndromes The Global Registry of Acute1.0225Coronary Events (GRACE). European Heart Journal, 2003, 24, 1414-1424.1.0225

#	Article	IF	CITATIONS
109	Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. European Heart Journal, 2003, 24, 828-837.	1.0	226
110	Reducing costs and improving outcomes of percutaneous coronary interventions. American Journal of Managed Care, 2003, 9, 365-72.	0.8	6
111	Missed Opportunities to Treat Atherosclerosis in Patients Undergoing Peripheral Vascular Interventions. Circulation, 2002, 106, 1909-1912.	1.6	123
112	Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary Events [GRACE]). American Journal of Cardiology, 2002, 90, 1056-1061.	0.7	44
113	Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. American Journal of Cardiology, 2002, 90, 1068-1073.	0.7	297
114	The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) Collaborative Quality Improvement Initiative in Percutaneous Coronary Interventions. Journal of Interventional Cardiology, 2002, 15, 381-386.	0.5	66
115	Development of a Multicenter Interventional Cardiology Database: The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) Experience. Journal of Interventional Cardiology, 2002, 15, 387-392.	0.5	87
116	Competitive bidding for interventional cardiology supplies: lessons learned during round 2. American Journal of Managed Care, 2002, 8, 384-8.	0.8	5
117	Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: rationale for new antithrombotic agents. Journal of Invasive Cardiology, 2002, 14 Suppl B, 55B-64B.	0.4	5
118	Predictors of length of stay after coronary stenting. American Heart Journal, 2001, 142, 799-805.	1.2	50
119	Balloon atrial septostomy in end-stage pulmonary hypertension guided by a novel intracardiac echocardiographic transducer. Catheterization and Cardiovascular Interventions, 2001, 52, 530-534.	0.7	34
120	Coil Embolization of a Periprosthetic Mitral Valve Leak Associated With Severe Hemolytic Anemia. Circulation, 2001, 104, E85-6.	1.6	45
121	Simple Bedside Additive Tool for Prediction of In-Hospital Mortality After Percutaneous Coronary Interventions. Circulation, 2001, 104, 263-268.	1.6	167
122	Left ventricular apical puncture: A procedure surviving well into the new millennium. Catheterization and Cardiovascular Interventions, 2000, 49, 68-73.	0.7	8
123	Guiding catheter thrombectomy during percutaneous coronary interventions for acute coronary syndromes. Catheterization and Cardiovascular Interventions, 2000, 49, 192-196.	0.7	14
124	Prevalence and significance of Exit Block During Arrhythmias Arising in Pulmonary Veins. Journal of Cardiovascular Electrophysiology, 2000, 11, 379-386.	0.8	15
125	Comparison of Endocardial Activation Times at Effective and Ineffective Ablation Sites Within the Pulmonary Veins. Journal of Cardiovascular Electrophysiology, 2000, 11, 155-159.	0.8	16
126	IL-8 Is an Angiogenic Factor in Human Coronary Atherectomy Tissue. Circulation, 2000, 101, 1519-1526.	1.6	194

#	Article	IF	CITATIONS
127	Comparison of artificial neural networks with logistic regression in prediction of in-hospital death after percutaneous transluminal coronary angioplasty. American Heart Journal, 2000, 140, 511-520.	1.2	32
128	Extracorporeal Life Support to Left Ventricular Assist Device Bridge to Heart Transplant : A Strategy to Optimize Survival and Resource Utilization. Circulation, 1999, 100, II-206-II-210.	1.6	194
129	Emergency extracorporeal membrane oxygenation (ECMO)-supported percutaneous coronary interventions in the fibrillating heart. Catheterization and Cardiovascular Interventions, 1999, 48, 402-405.	0.7	17
130	Validation of risk adjustment models for in-hospital percutaneous transluminal coronary angioplasty mortality on an independent data set. Journal of the American College of Cardiology, 1999, 34, 692-697.	1.2	46
131	Frequency, Predictors, and Appropriateness of Blood Transfusion After Percutaneous Coronary Interventions. American Journal of Cardiology, 1998, 81, 702-707.	0.7	31
132	Superimposed stents in the management of acute recoil after Palmaz-Schatz stenting. , 1998, 44, 407-410.		3
133	Vascular complications of coronary interventions. Heart and Lung: Journal of Acute and Critical Care, 1997, 26, 118-127.	0.8	55
134	Facilitated advancement of the Palmaz-Schatz stent delivery system with the use of an adjacent 0.018′ stiff wire. , 1996, 39, 106-110.		30
135	Incidence and treatment of 'no-reflow' after percutaneous coronary intervention Circulation, 1994, 89, 2514-2518.	1.6	476
136	Effect of prior coronary restenosis on the risk of subsequent restenosis after stent placement or directional atherectomy. American Journal of Cardiology, 1994, 73, 1147-1153.	0.7	32
137	Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. American Journal of Cardiology, 1994, 74, 748-754.	0.7	115
138	Peripheral vascular complications of directional coronary atherectomy and stenting: Predictors, management, and outcome. American Journal of Cardiology, 1994, 74, 448-453.	0.7	71
139	Palmaz-Schatz stenting for treatment of focal vein graft stenosis: Immediate results and long-term outcome. Journal of the American College of Cardiology, 1994, 23, 1296-1304.	1.2	136
140	Retroperitoneal hematoma after cardiac catheterization: Prevalence, risk factors, and optimal management. Journal of Vascular Surgery, 1994, 20, 905-913.	0.6	142
141	Neuropathy after cardiac catheterization: Incidence, clinical patterns, and long-term outcome. Journal of Vascular Surgery, 1994, 19, 1008-1014.	0.6	67
142	Long-term weight control study III (weeks 104 to 156). Clinical Pharmacology and Therapeutics, 1992, 51, 602-607.	2.3	61
143	Effect of Partial Ileal Bypass Surgery on Coronary Heart Disease. New England Journal of Medicine, 1991, 324, 562-564.	13.9	1
144	Randomisation and baseline characteristics in clinical trials. Lancet, The, 1990, 335, 1040-1041.	6.3	0

9

#	Article	IF	CITATIONS
145	Left ventricular mass and left ventricular diastolic function. Lancet, The, 1990, 336, 940-940.	6.3	7
146	Brief Footshock Analgesia: Long-Lasting Enhancement Induced by Cathinone, an Amphetamine-Like Agent. Pharmacology, 1988, 37, 114-124.	0.9	4
147	Blinding, unblinding, and the placebo effect: An analysis of patients' guesses of treatment assignment in a double-blind clinical trial. Clinical Pharmacology and Therapeutics, 1987, 41, 259-265.	2.3	91
148	Prolonged Analgesia Induced by Cathinone. Pharmacology, 1984, 29, 269-281.	0.9	18